Disc Medicine to Pursue Standard FDA Approval After Fast-Track Rejection for Bitopertin
Feb 17, 2026
Disc Medicine will pursue traditional U.S. approval for bitopertin after the FDA declined to approve the rare disease drug under an accelerated review pathway, with a potential decision expected around mid-2027.